Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 1:13:798975.
doi: 10.3389/fendo.2022.798975. eCollection 2022.

A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?

Maryam Joudi  1 , Maryam Moradi Binabaj  2 , Pejman Porouhan  3 , Babak PeyroShabany  4 , Mohsen Tabasi  5 , Danial Fazilat-Panah  6 , Mahtab Khajeh  7 , Arezoo Mehrabian  8 , Mansoureh Dehghani  9 , James S Welsh  10 , Batol Keykhosravi  7 , Azam Akbari Yazdi  7 , Mona Ariamanesh  11 , Ahmad Ghasemi  12 , Gordon Ferns  13 , Seyed Alireza Javadinia  7
Affiliations

A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?

Maryam Joudi et al. Front Endocrinol (Lausanne). .

Abstract

Aim: To determine the efficacy and safety of inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer.

Methods: In this multi- institutional cohort study, a total of 160 breast cancer patients (mean age of 50.01 ± 11.5 years old) were assessed for the SARS-CoV-2 Anti-Spike IgG and SARS-CoV2 Anti RBD IgG by ELISA after two doses of 0.5 mL inactivated, COVID-19 vaccine (BBIBP-CorV). All patients were followed up for three months for clinical COVID-19 infection based on either PCR results or imaging findings. Common Terminology Criteria for Adverse Events were used to assess the side effects.

Results: The presence of SARS-CoV-2 anti-spike IgG, SARS-CoV2 anti-RBD IgG, or either of these antibodies was 85.7%, 87.4%, and 93.3%. The prevalence of COVID-19 infection after vaccination was 0.7%, 0% and 0% for the first, second and third months of the follow-up period. The most common local and systemic side-effects were injection site pain and fever which were presented in 22.3% and 24.3% of patients, respectively.

Discussion: The inactivated SARS-CoV-2 vaccine (BBIBP-CorV) is a tolerable and effective method to prevent COVID-19.

Keywords: COVID-19 vaccine; Iran; SARS-CoV2; breast cancer; cancer; inactivated SARS-CoV-2 vaccine; malignancy; seroconversion.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Koh WJ, Anderson BO, Carlson RW. NCCN Resource-Stratified and Harmonized Guidelines: A Paradigm for Optimizing Global Cancer Care. Cancer (2020) 126:2416–23. doi: 10.1002/cncr.32880 - DOI - PubMed
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Dong E, Du H, Gardner L. An Interactive Web-Based Dashboard to Track COVID-19 in Real Time. Lancet Infect Dis (2020) 20(5):533–4. doi: 10.1016/S1473-3099(20)30120-1 - DOI - PMC - PubMed
    1. Figueroa JD, Gray E, Pashayan N, Deandrea S, Karch A, Vale DB, et al. . The Impact of the Covid-19 Pandemic on Breast Cancer Early Detection and Screening. Prev Med (2021) 151:106585. doi: 10.1016/j.ypmed.2021.106585 - DOI - PMC - PubMed
    1. Soroosh D, Javadinia SA. The COVID-19 Outbreak and Oncology Centers in Iran. Int J Cancer Manag (2020) 13(6):e103283. doi: 10.5812/ijcm.103283 - DOI

Publication types

LinkOut - more resources